ID: MRFR/MED/0834-HCR | February 2021 | Region: Global | 80 pages
Market Scenario:
Glaucoma refers to a condition which causes blindness. It is a chronic and permanent disorder whose prevalence’s is increasing with increasing age. Beside this different diseases like diabetes and deficiency of vitamins can also cause this disease. The major driving factor for the growth of this market is increasing aging population across the globe and increasing the prevalence of diabetes. Changing lifestyle and unhealthy food has given a push for the growth of this market. On the other hand, preference of minimum surgery and the high cost of the surgical treatment can hamper the growth of the market.
Global glaucoma surgery market is expected to grow at a CAGR of 7.9% during forecasted period of 2017-2023.
Key Players for global glaucoma surgery market
Novartis AG (Switzerland), Allergan (US), Merck & Co., Inc. (US), Abbott (US), Akorn, Inc. (US), Teva Pharmaceuticals (US), Bausch & Lomb (US), Pfizer, Santen (Japan), Carl Zeiss Meditec (Germany), Alcon (US), Ellex Medical Lasers (Australia), Lumenis (US), Topcon Medical Systems (US), Nidek (US), OPHTEC (US), Optos (US), Accutome (US), AqueSys (Taiwan), Canon (Japan), Essilor (France), Iridex Corporation (US)
Segmentation
Global glaucoma surgery market is segmented on the basis of target into trabecular meshwork, suprachoroidal space and others. On the basis of type of surgery it is segmented into angle closure glaucoma surgery, aqueous shunt surgery, laser surgery and other and on the basis of end user the market is segmented into hospital, ambulatory surgery centers and other.
Regional Analysis
Geographically global glaucoma surgery market is segmented into four major region namely North America, Europe, Asia Pacific and Middle East and Africa. North America commands the largest market for the glaucoma surgery due to a huge population suffering from diabetes and other eye diseases. Increasing healthcare expenditure and improved infrastructure has a synergistic impact on the growth of the market. Europe is the second largest market followed by Asia Pacific region. A huge population base and rapid development in healthcare sector has attracted many of the company to develop there market in Asia Pacific region.
Market Assessment
The report for global Glaucoma surgery market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.
Study objectives global Glaucoma surgery market
Intended Audience
Frequently Asked Questions (FAQ) :
The outlook of the global glaucoma surgery market looks very promising.
The global glaucoma surgery market is projected to grow at 7.9% CAGR during the assessment period (2017-2023).
Increasing aging population across the globe and Increasing prevalence of diabetes are the major tailwinds pushing the growth of the global glaucoma surgery market.
North America holds the largest share in the global glaucoma surgery market, followed by Europe and the Asia Pacific, respectively.
Allergan (US), Novartis AG (Switzerland), Merck & Co., Inc. (US), Akorn, Inc. (US), Abbott (US), Teva Pharmaceuticals (US), Pfizer, Bausch & Lomb (US), Santen (Japan), Alcon (US), Carl Zeiss Meditec (Germany), Ellex Medical Lasers (Australia), Topcon Medical Systems (US), Lumenis (US), Nidek (US), Optos (US), OPHTEC (US), Accutome (US), Canon (Japan), AqueSys (Taiwan), Iridex Corporation (US), and Essilor (France), are some of the major players operating in the glaucoma surgery market.
1 INTRODUCTION
1.1 DEFINITION
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.2.2.1 ASSUMPTIONS
1.2.2.2 LIMITATIONS
1.3 MARKET STRUCTURE:
2 RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH
3 MARKET DYNAMICS
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 MACROECONOMIC INDICATORS
4 MARKET FACTOR ANALYSIS
4.1 PORTERS FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY
5. GLOBAL GLAUCOMA SURGERY MARKET, BY TARGET
5.1 TRABECULAR MESHWORK
5.2 SUPRACHOROIDAL SPACE
5.3 OTHERS
6. GLOBAL GLAUCOMA SURGERY MARKET, BY TYPE OF SURGERY
6.1 ANGLE CLOSURE GLAUCOMA SURGERY
6.2 AQUEOUS SHUNT SURGERY
6.3 LASER SURGERY
6.4 OTHER
7. GLOBAL GLAUCOMA SURGERY MARKET, BY END USER
7.1 HOSPITAL
7.2 AMBULATORY SURGERY CENTERS
7.3 OTHER
8. GLOBAL GLAUCOMA SURGERY MARKET, BY REGION
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.2.1 US
8.2.2 CANADA
8.3 EUROPE
8.3.1 WESTERN EUROPE
8.3.1.1 GERMANY
8.3.1.2 FRANCE
8.3.1.3 ITALY
8.3.1.3 SPAIN
8.3.1.5 UK
8.3.1.6 REST OF WESTERN EUROPE
8.3.2 EASTERN EUROPE
8.4 ASIA
8.4.1 JAPAN
8.4.2 CHINA
8.4.3 INDIA
8.4.4 AUSTRALIA
8.4.5 REPUBLIC OF KOREA
8.5 REST OF ASIA-PACIFIC
8.6 MIDDLE EAST & AFRICA
8.6.1 UNITED ARAB EMIRATES
8.6.2 SAUDI ARABIA
8.6.3 OMAN
8.6.4 KUWAIT
8.6.5 QATAR
9. COMPETITIVE LANDSCAPE
9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
9.1.1 STRATEGIC PARTNERSHIP
9.1.2 MERGER & ACQUISITION
10 COMPANY PROFILE
10.1 ALLERGAN
10.1.1 OVERVIEW
10.1.2 PRODUCT OVERVIEW
10.1.3 FINANCIALS
10.1.4 KEY DEVELOPMENTS
10.2 TEVA PHARMACEUTICALS
10.2.1 OVERVIEW
10.2.2 PRODUCT OVERVIEW
10.2.3 FINANCIALS
10.2.4 KEY DEVELOPMENTS
10.3 NOVARTIS AG
10.3.1 OVERVIEW
10.3.2 PRODUCT OVERVIEW
10.3.3 FINANCIALS
10.3.4 STRATEGY
10.3.5 KEY DEVELOPMENT
10.4 PFIZER
10.4.1 OVERVIEW
10.4.2 PRODUCT OVERVIEW
10.4.3 FINANCIALS
10.4.4 KEY DEVELOPMENTS
10.5 ELLEX MEDICAL LASERS.
10.5.1 OVERVIEW
10.5.2 PRODUCT OVERVIEW
10.5.3 FINANCIALS
10.5.4 KEY DEVELOPMENTS
10.6 OTHERS